Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Arteriovenous graft (AVG) serves as a critical vascular access for hemodialysis patients when autogenous arteriovenous fistula is not feasible. However, AVG infection remains a serious complication, leading to increased morbidity, hospitalization, and access loss. Current reports on the clinical profile, management outcomes, and risk factors for AVG abandonment following infection are limited. This study aimed to investigate the clinical characteristics, intervention outcomes, and predictors of AVG abandonment in a retrospective cohort.
A retrospective analysis was conducted in patients with upper arm AVGs at the Hemodialysis Center of the First Affiliated Hospital of Zhengzhou University from January 2018 to December 2023. The incidence and clinical features of AVG infections were analyzed, treatment outcomes of different intervention strategies were compared, and factors associated with AVG abandonment after infection were examined.
A total of 704 patients with upper arm AVGs were included, with a median follow-up time of 755 days (IQR 494–1158). During follow-up, 37 episodes of AVG infection occurred in 37 patients, including 14 males and 23 females, with a mean age of 58.2 ± 11.2 years. The cumulative incidence of AVG infection was 5.3% (37/704), and the incidence density was 2.25 episodes per 100 patient-years. The infection rates at 3, 6, and 12 months after AVG creation were 0.6% (4/704), 1.1% (8/704), and 2.2% (16/704), respectively. Inflammation at the graft site was observed in 97.3% (36/37) of patients, while 64.9% (24/37) presented with systemic symptoms. Among 35 patients who underwent pathogenic microbial culture, the positivity rates of blood culture and tissue/secretion culture were 84.2% (16/19) and 78.1% (25/32), respectively, with Staphylococcus aureus being the most common strain. All patients received antimicrobial therapy, and 75.7% (28/37) were treated with vancomycin or linezolid. After infection, 18 AVGs were directly abandoned, 8 patients received conservative treatment, and 11 underwent graft partial excision and replacement. Following intervention, 40.5% (15/37) achieved AVG salvage without recurrence within 90 days. Multivariate logistic regression analysis indicated that female sex [OR = 23.065 (1.867–284.878), P = 0.014] and the use of GORE® ACUSEAL® graft [OR = 21.097 (1.674–265.831), P = 0.018] were risk factors for AVG abandonment after infection.
The overall incidence of AVG infection is relatively low. With appropriate and active intervention, functional AVG salvage can be achieved in selected cases. Female patients and those with GORE® ACUSEAL® grafts are more likely to experience AVG abandonment after infection.
